Insider Selling: Orthofix Medical Inc. (NASDAQ:OFIX) Insider Sells 4,287 Shares of Stock

Orthofix Medical Inc. (NASDAQ:OFIX - Get Free Report) insider Lucas Vitale sold 4,287 shares of the firm's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $16.60, for a total transaction of $71,164.20. Following the sale, the insider now directly owns 135,317 shares of the company's stock, valued at $2,246,262.20. The trade was a 3.07 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Orthofix Medical Stock Performance

Shares of NASDAQ:OFIX traded up $0.11 during trading hours on Monday, hitting $16.74. The stock had a trading volume of 304,594 shares, compared to its average volume of 255,195. Orthofix Medical Inc. has a 1-year low of $12.08 and a 1-year high of $20.73. The firm has a market capitalization of $653.23 million, a price-to-earnings ratio of -5.35 and a beta of 1.06. The stock's fifty day simple moving average is $17.77 and its 200 day simple moving average is $17.37. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.11 and a current ratio of 2.39.

Institutional Investors Weigh In On Orthofix Medical

Several hedge funds have recently modified their holdings of the stock. Engine Capital Management LP lifted its stake in Orthofix Medical by 2.4% during the fourth quarter. Engine Capital Management LP now owns 3,450,744 shares of the medical device company's stock valued at $60,250,000 after buying an additional 82,079 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Orthofix Medical by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 2,126,785 shares of the medical device company's stock valued at $37,134,000 after acquiring an additional 12,286 shares during the period. Juniper Investment Company LLC lifted its position in shares of Orthofix Medical by 123.5% in the 4th quarter. Juniper Investment Company LLC now owns 1,937,249 shares of the medical device company's stock valued at $33,824,000 after acquiring an additional 1,070,656 shares in the last quarter. Boone Capital Management LLC boosted its stake in Orthofix Medical by 13.6% in the 4th quarter. Boone Capital Management LLC now owns 1,057,313 shares of the medical device company's stock worth $18,461,000 after purchasing an additional 126,806 shares during the period. Finally, Geode Capital Management LLC grew its position in Orthofix Medical by 0.3% during the 4th quarter. Geode Capital Management LLC now owns 841,637 shares of the medical device company's stock worth $14,699,000 after purchasing an additional 2,448 shares in the last quarter. 89.76% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Canaccord Genuity Group reiterated a "buy" rating and issued a $24.00 price target on shares of Orthofix Medical in a report on Wednesday, February 26th. StockNews.com upgraded shares of Orthofix Medical from a "hold" rating to a "buy" rating in a research note on Tuesday, February 25th. Finally, Roth Mkm reiterated a "buy" rating and set a $22.00 price target on shares of Orthofix Medical in a research report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $23.33.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.